Tegaserod

ইঙ্গিত

Constipation Irritable Bowel Syndrome

Tegazel tablet is used to treat irritable bowel syndrome with constipation (IBS-C) in adult women under 65 years of age.

⚠️ কোনো ওষুধ গ্রহণের আগে সর্বদা নিবন্ধিত চিকিৎসকের পরামর্শ নিন।

ফার্মাকোলজি

Tegaserod acts on serotonin type-4 (5-HT4) receptors in the gut, where it stimulates the peristaltic reflex and intestinal secretion, dampens visceral sensitivity, and boosts basal motor activity, helping restore normal motility throughout the gastrointestinal tract. Laboratory binding and functional studies show that, at plasma concentrations seen in clinical use, tegaserod also blocks 5-HT2B receptors in humans, and it is expected to bind only weakly to 5-HT1 receptors. It shows no affinity for 5-HT3 or dopamine receptors, and its main metabolite, M29, has negligible affinity for 5-HT4 receptors in vitro. Animal studies confirmed that tegaserod enhances basal motor activity, normalizes disrupted gut motility, and reduces visceral sensitivity during colorectal distension.

Pregnancy & Breastfeeding

Available data from case reports of tegaserod use during pregnancy have not shown a link to major birth defects, miscarriage, or other adverse outcomes for the mother or baby. It is not known whether tegaserod passes into human breast milk, or what effect it might have on a nursing infant or on milk supply. In rats, tegaserod and its breakdown products do pass into milk, reaching levels much higher than those found in the mother's blood.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

ডোজ নির্দেশিকা

⚠️ শুধুমাত্র সরকারি উৎস থেকে নির্দেশিকা পরিসীমা। ব্যক্তিগতকৃত ডোজের জন্য আপনার ডাক্তারের পরামর্শ নিন।

Adults: Dosage: In adult women under 65, the recommended dose is 6 mg orally, twice daily, taken at least 30 minutes before meals. If symptoms are not adequately controlled after 4 to 6 weeks of treatment, Tegaserod should be discontinued. Pediatric use: The safety and effectiveness of Tegaserod in pediatric patients have not been established. Geriatric use: Tegaserod is not indicated for use in patients aged 65 years or older. Renal impairment: Tegaserod should not be used in patients with severe renal impairment (eGFR below 15 mL/min/1.73 m2) or end-stage renal disease. Hepatic impairment: Tegaserod should not be used in patients with moderate or severe hepatic impairment.

পার্শ্বপ্রতিক্রিয়া ও পারস্পরিক ক্রিয়া

পার্শ্বপ্রতিক্রিয়া

No side-effect data recorded yet.

প্রধান পারস্পরিক ক্রিয়া

Checker →